Incorporating ADCs into the treatment of mBC: Practical considerations for the community oncologist

Optimizing metastatic breast cancer treatment: Where do ADCs fit?

As antibody–drug conjugates (ADCs) become key in the management of metastatic breast cancer (mBC), it’s essential to understand how to integrate them effectively into clinical practice.

Join oncologists Prof. Giuseppe Curigliano and Dr Alison Conlin as they address real-world questions from the oncology community, covering:
Incorporating ADCs across HR+/HER2–, HER2+ and triple-negative mBC subtypes

The role of biomarkers in guiding ADC therapy selection

How to choose between ADC options when patients are eligible for multiple treatments

Managing ADC-associated toxicities in everyday practice

This insightful peer-to-peer discussion provides practical guidance aligned with current treatment guidelines to help you deliver confident evidence-based care.

👉 Watch the activity now: https://touchoncologyime.org/adcs-in-...

Advance your knowledge. Strengthen your practice. Improve patient outcomes.

This activity is funded by an independent medical education grant from Gilead Sciences, Inc.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

#BreastCancerCare #mBC #ADCs #OncologyEducation #MedicalEducation #GlobalAccess #CancerTreatment